Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195498 | 1.00 | CA1 (0.44) | CA1CA2CA9KDM4ESTS | |
| SCHEMBL6942043 | 0.86 | CA1 (0.44) | CA1CA2CA9KDM4EDRD2 | |
| SCHEMBL31195545 | 0.84 | MRGPRX4 (0.40) | STSDRD2DRD1DRD4DRD5 | |
| SCHEMBL29365046 | 0.83 | CA1 (0.50) | CA1CA2CA9KDM4ESTS | |
| SCHEMBL31204254 | 0.83 | CA1 (0.46) | CA1CA2CA9KDM4EDRD2 | |
| SCHEMBL8502379 | 0.83 | EPAS1 (0.47) | CA1CA2CA9KDM4EEPAS1 | |
| SCHEMBL31204476 | 0.83 | TSHR (0.46) | KDM4ESTSEPAS1MRGPRX4ALDH1A1 | |
| SCHEMBL1772862 | 0.83 | CA1 (0.50) | CA1CA2CA9KDM4ESTS | |
| SCHEMBL1411728 | 0.83 | CA1 (0.46) | CA1CA2CA9KDM4EDRD2 | |
| SCHEMBL4581096 | 0.83 | ACHE (0.55) | CA1CA2CA9ACHEUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2949655-B1 | REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | HOKKO CHEM IND CO (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9707551-B2 | Reaction catalyst for cross-coupling and method for manufacturing aromatic compound | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| CN-104350040-B | Aromatic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-06-01 | — | — | CN | disclosed |
| CN-105492075-A | Inhibitors of viral replication, their process of preparation and their therapeutical uses | MUTABILIS SA | 2016-04-13 | — | — | CN | disclosed |
| US-20150360214-A1 | REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2949655-A1 | REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | Hokko Chemical Industry Co., Ltd. (JP) | 2015-12-02 | — | — | EP | disclosed |
| CN-105008378-A | Reaction catalyst for cross coupling and method for manufacturing aromatic compound | HOKKO CHEM IND CO | 2015-10-28 | — | — | CN | disclosed |
| CN-104350040-A | Aromatic ring compound | TAKEDA PHARMACEUTICAL | 2015-02-11 | — | — | CN | disclosed |
| US-20140011097-A1 | TERT-BUTYLPHENYL SULFONATE COMPOUND, NONAQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY USING THE SAME, AND LITHIUM SECONDARY BATTERY USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-8546599-B2 | Tert-butylphenyl sulfonate compound, nonaqueous electrolyte solution for lithium secondary battery using the same, and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-6365776-B1 | FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TYR, DDC, PNMT | CA1 4452/4885CA2 3856/4885CA9 2329/4885 |
| US-20150360214-A1 | REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND | ALK, HRH4, HRH3 | CA1 952/4885CA2 163/4885CA9 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.